Compare XHR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XHR | DRTS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2014 | 2021 |
| Metric | XHR | DRTS |
|---|---|---|
| Price | $17.58 | $15.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $15.67 | $8.67 |
| AVG Volume (30 Days) | ★ 636.1K | 564.5K |
| Earning Date | 05-01-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 326.67 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,078,500,000.00 | N/A |
| Revenue This Year | $3.94 | N/A |
| Revenue Next Year | $2.68 | $699.98 |
| P/E Ratio | $95.81 | ★ N/A |
| Revenue Growth | ★ 3.80 | N/A |
| 52 Week Low | $11.75 | $3.43 |
| 52 Week High | $22.06 | $15.17 |
| Indicator | XHR | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 26.84 | 59.17 |
| Support Level | $14.26 | $13.65 |
| Resistance Level | $19.82 | $15.01 |
| Average True Range (ATR) | 0.40 | 0.68 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 5.88 | 80.26 |
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other regions. Xenia's revenue is divided between the sale of rooms, food and beverages, and other sources.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.